Original-Research: Defence Therapeutics Inc. (von GBC AG)
Original-Research: Defence Therapeutics Inc. - von GBC AG
Einstufung von GBC AG zu Defence Therapeutics Inc.
Unternehmen: Defence Therapeutics Inc.
Anlass der Studie: Research Comment
Analyst: Julien Desrosiers, Cosmin Filker
GBC Research Watchlist: Defence Therapeutics
Defence Therapeutics is led by Sebastien Plouffe. Mr. Plouffe has been a
successful Investment Advisor and CEO notably in the resource sector,
leading several junior companies to profitable exits. Mr. Plouffe is
supported by Dr. Moutih Rafei, VP R&D and Dr. Simon Beaudoin CTSO. Dr.
Rafei is a world-renowned Immuno-Oncologist and Dr. Beaudoin is the co-
inventor of the ACCUMTM-Technology. The Company board also includes high
profile specialists such as Dr. Sarkis Meterissian, world renowned
oncologist, Director of the Breast Center of the MUHC and MUHC Head of the
Tumor Site Group and Dr. Raimar Löbenberg Founder and Director of the Drug
Development and Innovation Centre (University of Alberta).
Because The Company can attach most molecules to ACCUM and possibly enhance
intracellular delivery, the potential applications of their molecule are
The company is currently developing five distinct products, all leveraging
their ACCUMTM-Technology. All are currently in Pre-Clinical or Discovery
phases. They have all shown tremendous potential in rodent and non-rodent
Antibody-drug conjugates (ADC) are one of the fastest growing anticancer
drugs. This approach comprises a mAb conjugated to the cytotoxic payload
via a chemical linker that directed toward a target antigen expressed on
the cancer cell surface, reducing systemic exposure and therefore toxicity.
ADCs are complex molecules that require careful attention to various
components. Selection of an appropriate target, an mAb, cytotoxic payload,
and the way the antibody is linked to the payload are key determinants of
the safety and efficacy of ADCs.
One of the major and most common encounters for successful development of
vaccine and ADC's are the antigen/ADC degradation in the target cell
endosomes. The drug developer has then two options: increase the dosage,
which results in increased side effects or keep the dosage untouched with
the consequence of a less than expected efficiency. These two scenarios can
lead directly to FDA denial.
The ACCUMTM platform, developed by Defence Therapeutics aims directly at
tackling this issue. Solving the limited nucleus delivery hurdle would have
a profonde effect for the ADC drug development sector leading to possible
approval of already declined ADCs or increased probabilities of approval
for new ones.
The sum of all these attributes puts the ACCUMTM Technology at the center
of future cancer treatment including the design of enhanced ADCs and
We are currently working on the Initial Coverage of Defence Therapeutics,
which is coming soon. Based on this, we will start ongoing coverage on
Defence Therapeutics as we believe now is the ideal time to show the
valuation potential in this growth story. The company has already referred
to several important upcoming milestones that could be included in our
Die vollständige Analyse können Sie hier downloaden:
Kontakt für Rückfragen
0821 / 241133 0
Offenlegung möglicher Interessenskonflikte nach § 85 WpHG und Art. 20 MAR Beim oben analysierten Unternehmen ist folgender möglicher Interessenkonflikt gegeben: (5a,11); Einen Katalog möglicher Interessenkonflikte finden Sie unter:
Date (time) Completion: 21/01/22 (11:12 am)
Date (time) first transmissi-on: 24/01/22 (11:00 am)
-------------------übermittelt durch die EQS Group AG.-------------------
Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw.
Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung
oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
Disclaimer: You are now leaving PharmiWeb.com website and are going to a website that is not operated by us. We are not responsible for the content or availability of linked sites.
ABOUT THIRD PARTY LINKS ON OUR SITE
PharmiWeb.com offers links to other third party websites that may be of interest to our website visitors. The links provided in our website are provided solely for your convenience and may assist you in locating other useful information on the Internet. When you click on these links you will leave the PharmiWeb.com website and will be redirected to another site. These sites are not under the control of PharmiWeb.com.
PharmiWeb.com is not responsible for the content of linked third party websites. We are not an agent for these third parties nor do we endorse or guarantee their products. We make no representation or warranty regarding the accuracy of the information contained in the linked sites. We suggest that you always verify the information obtained from linked websites before acting upon this information.
Also, please be aware that the security and privacy policies on these sites may be different than PharmiWeb.com policies, so please read third party privacy and security policies closely.
If you have any questions or concerns about the products and services offered on linked third party websites, please contact the third party directly.